Display options
Cite
Bubalo JS, Kullar R, Maziarz RT. A pilot study of the efficacy and safety of empiric daptomycin therapy in oncology patients with fever and severe neutropenia. Ther Adv Infect Dis. 2013;1(6):183-90doi: 10.1177/2049936113504090.
Bubalo, J. S., Kullar, R., & Maziarz, R. T. (2013). A pilot study of the efficacy and safety of empiric daptomycin therapy in oncology patients with fever and severe neutropenia. Therapeutic advances in infectious disease, 1(6), 183-90. https://doi.org/10.1177/2049936113504090
Bubalo, Joseph S, et al. "A pilot study of the efficacy and safety of empiric daptomycin therapy in oncology patients with fever and severe neutropenia." Therapeutic advances in infectious disease vol. 1,6 (2013): 183-90. doi: https://doi.org/10.1177/2049936113504090
Bubalo JS, Kullar R, Maziarz RT. A pilot study of the efficacy and safety of empiric daptomycin therapy in oncology patients with fever and severe neutropenia. Ther Adv Infect Dis. 2013 Dec;1(6):183-90. doi: 10.1177/2049936113504090. PMID: 25165552; PMCID: PMC4040728.
Copy Download .nbib Format: NLM
Share it on

Ther Adv Infect Dis. 2013 Dec;1(6):183-90. doi: 10.1177/2049936113504090.

A pilot study of the efficacy and safety of empiric daptomycin therapy in oncology patients with fever and severe neutropenia.

Therapeutic advances in infectious disease

Joseph S Bubalo, Ravina Kullar, Richard T Maziarz

Affiliations

  1. Oregon Health and Science University, OHSU Pharmacy Services, CR 9-4 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.
  2. Clinical Assistant Professor, College of Pharmacy, Oregon State University/Oregon Health and Science University, Portland, OR, USA.
  3. Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.

PMID: 25165552 PMCID: PMC4040728 DOI: 10.1177/2049936113504090

Abstract

OBJECTIVES: Patients with extended periods of time spent with low or absent absolute neutrophil counts (ANCs) are at risk for bacterial infections. Febrile neutropenia is a complication in this patient population, requiring administration of antibiotics. The use of daptomycin in treating patients with febrile neutropenia is not well described. Our objective was to describe the clinical course of febrile neutropenic patients that received daptomycin therapy.

METHODS: This was an open-labeled, pilot study of 30 patients with documented febrile neutropenia treated with empiric daptomycin. Eligible patients received daptomycin 6 mg/kg/day, in addition to concomitant broad-spectrum antimicrobials. The Kaplan-Meier method was used to estimate the median days to reach an afebrile state and negative bacterial cultures.

RESULTS: A total of 30 febrile neutropenic patients were enrolled and received daptomycin as part of an empiric antimicrobial regimen. All patients had severe neutropenia with ANC <100 cells/mm(3). Two patients were removed from study due to the development of pneumonia. Clinically, 87% patients improved on daptomycin in combination with Gram-negative coverage, with 73% of patients succeeding therapy. A total of 18 of 19 (95%) subjects with positive blood cultures had microbiological eradication, with the median time to reach an afebrile state of 4.3 days (range 1-13). Four patients were discontinued from daptomycin due to a suspected related adverse event or to clinical failure.

CONCLUSIONS: This pilot study supports future evaluation of the use of empiric daptomycin therapy in combination with Gram-negative coverage compared with vancomycin in patients with neutropenic fever in a large, randomized controlled trial.

Keywords: Gram-positive infections; daptomycin efficacy and safety; empiric daptomycin; neutropenic fever; oncology patients

References

  1. Am J Med. 2007 Oct;120(10 Suppl 1):S4-5 - PubMed
  2. Clin Infect Dis. 2006 Mar 1;42(5):597-607 - PubMed
  3. J Clin Oncol. 2010 Apr 20;28(12):2008-14 - PubMed
  4. Clin Infect Dis. 2003 Oct 15;37(8):1144-5 - PubMed
  5. J Clin Oncol. 2001 Jul 15;19(14):3415-21 - PubMed
  6. Clin Infect Dis. 2008 Jan 15;46(2):193-200 - PubMed
  7. Scand J Infect Dis. 2006;38(1):7-14 - PubMed
  8. Support Care Cancer. 2011 Nov;19(11):1761-7 - PubMed
  9. Clin Infect Dis. 2002 Mar 15;34(6):730-51 - PubMed
  10. Clin Adv Hematol Oncol. 2008 Nov;6(11):813-5 - PubMed
  11. Pharmacotherapy. 2007 Jun;27(6):927-32 - PubMed
  12. Clin Infect Dis. 2011 Feb 15;52(4):e56-93 - PubMed
  13. Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S25-31 - PubMed
  14. J Infect. 2007 Jun;54(6):567-71 - PubMed
  15. Antimicrob Agents Chemother. 2007 May;51(5):1787-94 - PubMed
  16. Antimicrob Agents Chemother. 2003 May;47(5):1598-603 - PubMed
  17. Clin Infect Dis. 2011 Apr 15;52(8):975-81 - PubMed
  18. Ann Pharmacother. 2007 Sep;41(9):1531-5 - PubMed

Publication Types